TOKYO (AFX) - Astellas Pharma Inc said it has has terminated its agreement with QLT Inc of Canada on the licensing and supply of the acne treatment Aczone.
Astellas and QTL signed in October 2001 an agreement on the co-development and exclusive marketing of Aczone in the North American market.
Astellas, Japan's second-largest drugmaker, said in a statement that in feels that the labelling for Aczone suggested by the US Food and Drug Administration may initially affect the market profile of the product.
The company said it will promote more aggressively Protopic, for the treatment of atopic dermatitis, as its core product.
Yasuhiko.Seki@xfn.com
ys/jm
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
Astellas and QTL signed in October 2001 an agreement on the co-development and exclusive marketing of Aczone in the North American market.
Astellas, Japan's second-largest drugmaker, said in a statement that in feels that the labelling for Aczone suggested by the US Food and Drug Administration may initially affect the market profile of the product.
The company said it will promote more aggressively Protopic, for the treatment of atopic dermatitis, as its core product.
Yasuhiko.Seki@xfn.com
ys/jm
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
© 2005 AFX News
